In addition to offering a number of benefits, such as access to cutting-edge manufacturing sites and government assistance with infrastructure and production development, the SEZ resident status creates new prospects for the growth and consolidation of positions in the pharmaceutical industry market.

The business project of the Pharmasyntez Group was presented by Oleg Astafurov, Vice-President of Government Relations of the Pharmasyntez Group and Timofei Batalov, Production Director of Pharmasyntez-Biocapital at gaining the Technopolis-Moscow SEZ resident status. In order to fulfill the offset contract with the Moscow Healthcare Department, Pharmasyntez JSC will implement the investment project to establish production of import-substituting antineoplastic medicines at the Alabushevo site (Zelenograd, Moscow). In accordance with this contract, the first medication deliveries for the Moscow healthcare system's requirements are anticipated to begin in early 2026.

“The Pharmasyntez Group, a domestic pharmaceutical industry leader specializing primarily in the production of socially significant medicines for the needs of the country’s medical and preventive treatment institutions, will construct and put into operation one of its new plants in 2025. The sixth pharmaceutical plant will be built at the Technopolis-Moscow SEZ’s Alabushevo site, as ordered by the Moscow government.  The new manufacturing site will specialize in the production of antineoplastic drugs, strengthening the Group's position in the oncology segment, where Pharmasyntez plants already produce one-third of all oncology treatment packages. This is our first joint project with the Moscow City Government, and we plan to deepen and expand cooperation to provide the Moscow healthcare system with effective and safe medicines, including innovative ones", 

— noted Oleg Astafurov.